AI assistant
LEXICON PHARMACEUTICALS, INC. — Director's Dealing 2025
Jun 6, 2025
32814_dirs_2025-06-06_bb080ec7-e2c1-4561-8c09-3576c96e6372.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: LEXICON PHARMACEUTICALS, INC. (LXRX)
CIK: 0001062822
Period of Report: 2025-06-01
Reporting Person: Martens Rachel Yap (VP, Partnerships & Corp Strat)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 0 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Restricted Stock Units | $ | Common Stock (201270) | Direct | ||
| Stock Option (Right to Buy) | $.695 | 2035-02-13 | Common Stock (201270) | Direct | |
| Stock Option (Right to Buy) | $1.69 | 2034-10-07 | Common Stock (150806) | Direct |
Footnotes
F1: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.
F2: Each restricted stock unit represents a contingent right to receive one share of common stock.
F3: Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter.
F4: Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant (10/7/2025) and vests 148th per month for each month of service thereafter.